IB
Therapeutic Areas
Intensity Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| INT230-6 | Metastatic Soft Tissue Sarcomas | Phase 2/3 |
Leadership Team at Intensity Therapeutics
LH
Lewis H. Bender
Founder, President, Chief Executive Officer
JP
Jonathan P. Arm
Chief Financial Officer